# Biocardia (BCDA) — News

BCDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bcda/news

## Recent headlines

- [Europe's STOXX 600 pares gains after US CPI, last up 0.46%](https://www.ainvest.com/news/europe-stoxx-600-pares-gains-cpi-0-46-2610) — AInvest Wire, Oct 14, 2026
  European stocks trimmed gains on Thursday as investors digested the latest U.S. inflation data, which showed a 0.4% rise in consumer prices for January, bringing the annual rate to 7.2% . The pan-European STOXX 600 index had earlier risen 0.46% but pared those gains as traders weighed the…
- [Ocado sales up 12.4% in 12 weeks to October 4 year-on-year, says Worldpanel](https://www.ainvest.com/news/ocado-sales-12-4-12-weeks-october-4-year-year-worldpanel-2610) — AInvest Wire, Oct 13, 2026
- [BioCardia - FDA targets initial review within 15 days and feedback or meeting within 70 days](https://www.ainvest.com/news/biocardia-fda-targets-initial-review-15-days-feedback-meeting-70-days-2610) — AInvest Wire, Oct 1, 2026
  BioCardia, Inc. (NASDAQ: BCIA) has confirmed the timing of its pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding its Helix Cell Delivery System. According to the company, the FDA has indicated that its initial review of the submission is expected to occur within 15…
- [BioCardia - FDA raises no concerns regarding Helix safety data or device performance](https://www.ainvest.com/news/biocardia-fda-raises-concerns-helix-safety-data-device-performance-2610) — AInvest Wire, Oct 1, 2026
  BioCardia, Inc. (Nasdaq: BCDA) recently reported that the U.S. Food and Drug Administration (FDA) raised no concerns regarding the safety data or device performance of its Helix Transendocardial Delivery Catheter System during a Pre-Submission Meeting. The meeting, held in May 2026, outlined two…
- [BioCardia - To submit de novo pre-submission for Helix catheter system to FDA this quarter](https://www.ainvest.com/news/biocardia-submit-de-novo-pre-submission-helix-catheter-system-fda-quarter-2609) — AInvest Wire, Sep 23, 2026
  BioCardia, Inc. (Nasdaq: BCDA) has completed its Pre-Submission to the U.S. Food and Drug Administration (FDA) under the Q-Submission program for its Helix Transendocardial Delivery Catheter system, a key component of the company’s cell and gene therapy delivery platform. The submission is part of…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).